黄连解毒汤加减用于脓毒症患者早期肠内营养的疗效：一项随机对照研究。

The efficacy of modified HuangLian JieDu decoction for early enteral nutrition in patients with sepsis: A randomized controlled study.

机构信息

ICU, Traditional Chinese Medical Hospital, Zhejiang Province, China.

Department of Science and Education, Traditional Chinese Medical Hospital, Zhejiang Province, China.

出版信息

Medicine (Baltimore). 2022 Dec 30;101(52):e32583. doi: 10.1097/MD.0000000000032583.

DOI:10.1097/MD.0000000000032583

PMID:36596025

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9803492/

Abstract

OBJECTIVE

This study aimed to evaluate the efficacy of modified HuangLian JieDu decoction (MHLJDD) as a supplementary medication for early enteral nutrition in septic patients.

METHODS

This study was designed as a randomized controlled preliminary study. Septic patients were randomly divided into control (treated with the base treatment) and intervention (co-treated with MHLJDD and the base treatment) groups. The primary outcomes of this study were 60-day (d) mortality rate, length of mechanical ventilation (MV), and length of stay in the intensive care unit (ICU).

RESULTS

Of the 86 included patients, 44 and 42 were allocated to the intervention and control groups, respectively. Lengths of MV and ICU stay were significantly shorter in the intervention group than in the control group (10.31 ± 3.92 d vs 8.66 ± 2.84 d, P = .028; and 11.88 ± 5.25 d vs 10.41 ± 3.14 d, P = .029; respectively). However, the difference in 60-d mortality rate between the 2 groups was not statistically significant (20.45% vs 38.10%, P = .071). The enteral-nutrition tolerance score of the control group was higher than that of the intervention group (6.81 ± 4.28 vs 4.68 ± 4.04, P = .020). Incidence of hyperglycemia and gastric retention (gastric residual volume > 250 mL) was higher in the control group than in the intervention group (59.52% vs 29.55%, P = .005; and 28.57% vs 11.36%, P = .020, respectively).

CONCLUSIONS

MHLJDD can shorten the MV and ICU stay of septic patients.

摘要

目的

本研究旨在评估黄连解毒汤加减（MHLJDD）作为脓毒症患者早期肠内营养辅助治疗的疗效。

方法

本研究设计为随机对照初步研究。脓毒症患者被随机分为对照组（接受基础治疗）和干预组（MHLJDD 联合基础治疗）。本研究的主要结局为 60 天死亡率、机械通气（MV）时间和重症监护病房（ICU）住院时间。

结果

在 86 例纳入患者中，44 例和 42 例分别被分配到干预组和对照组。干预组 MV 和 ICU 住院时间明显短于对照组（10.31±3.92 天比 8.66±2.84 天，P=0.028；11.88±5.25 天比 10.41±3.14 天，P=0.029；分别）。然而，两组 60 天死亡率差异无统计学意义（20.45%比 38.10%，P=0.071）。对照组的肠内营养耐受评分高于干预组（6.81±4.28 比 4.68±4.04，P=0.020）。对照组高血糖和胃潴留（胃残留量＞250mL）的发生率高于干预组（59.52%比 29.55%，P=0.005；28.57%比 11.36%，P=0.020，分别）。